Barclays analyst Lauren Lieberman maintains $Clorox (CLX.US)$ with a sell rating, and maintains the target price at $137.
According to TipRanks data, the analyst has a success rate of 53.4% and a total average return of 2.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Clorox (CLX.US)$'s main analysts recently are as follows:
The forecast for Clorox leading into the Q3 earnings season within the household, personal care, and beauty sector is generally optimistic. It is acknowledged that the sequential slowdown in organic sales is due to the diminishing impact of pricing benefits. Companies that are leading in their class are experiencing volume growth, and a majority are seeing margin expansion.
Looking ahead to the Q3 earnings for the consumer staples sector, the observation is that there appears to be minimal change in the overarching narratives since the previous earnings season over the summer.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.